Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: A randomized controlled trial

European Journal of Heart Failure

Volumn 11, Issue 7, 2009, Pages 684-690

  Hawkins, Nathaniel M ^a   Macdonald, Michael R ^b   Petrie, Mark C ^b   Chalmers, George W ^b   Carter, Roger ^b   Dunn, Francis G ^c   Mcmurray, John J V ^d  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c STOBHILL HOSPITAL   (United Kingdom)

^d WESTERN INFIRMARY   (United Kingdom)

Author keywords

Beta blockers; Chronic obstructive pulmonary disease; Heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISOPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; STEROID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTERIAL GAS; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; ECHOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOXEMIA; LUNG FUNCTION; MALE; MAXIMUM TOLERATED DOSE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RADIOISOTOPE VENTRICULOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SIDE EFFECT; TREATMENT OUTCOME; BLOOD GAS ANALYSIS; COMPLICATION; HEALTH STATUS INDICATOR; LUNG; PHYSIOLOGY; PROSPECTIVE STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SPIROMETRY; VITAL CAPACITY;

ADRENERGIC BETA-ANTAGONISTS; AGED; BISOPROLOL; BLOOD GAS ANALYSIS; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS INDICATORS; HEART FAILURE; HUMANS; LUNG; MALE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SPIROMETRY; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 67650093474     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp066     Document Type: Article

References (47)

1. GOLD Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Workshop Report. Updated 2006. http://www.goldcopd. com/2006.
2. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388-2442.
3. Hawkins NM, Petrie MC,Jhund PS, Chalmers GW, Dunn FG, McMurrayJJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009; 11:130-139.
4. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Guideline Update for the Diagnosis and Management ofChronic Heart Failure in the Adult: a report ofthe American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management ofHeart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154-e235.
5. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, van Gilst WH, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure Survey programmea survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24:464-474.
6. McNeill RS. Effect of a beta-adrenergic-blocking agent, propranolol, on asthmatics. Lancet 1964; 13:1101-1102.
7. Raine JM, Palazzo MG, Kerr JH, Sleight P. Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane. Br Med J (Clin Res Ed) 1981; 282:548-549.
8. Zaid G, Beall GN. Bronchial response to beta-adrenergic blockade. N Engl J Med 1966; 275:580-584.
9. Williams JE, Singh SJ, Sewell L, Morgan MD. Health status measurement: sensitivity of the self-reported Chronic Respiratory Questionnaire (CRQ-SR) in pulmonary rehabilitation. Thorax 2003; 58:515-518.
10. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. Eur Respir J 2005; 26:319-338.
11. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J2005; 26:948-968.
12. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir JSuppl 1993; 16:5-40.
13. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC,Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl JMed 2007; 356:775-789.
14. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000; 320:1297-1303.
15. Sinclair DJ. Comparison of effects of propranolol and metoprolol on airways obstruction in chronic bronchitis. Br Med J1979; 1:168.
16. Wunderlich J, Macha HN, Wudicke H, Huckauf H. Beta-adrenoceptor blockers and terbutaline in patients with chronic obstructive lungdisease. Effects and interaction after oral administration. Chest 1980; 78:714-720.
17. Fogari R, Zoppi A, Tettamanti F, Poletti L, Rizzardi G, Fiocchi G. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther 1990; 4:1145-1149.
18. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M,Pochmalicki G, Dargie H. Heart rate and cardiac rhythm relationships with biso- prolol benefit in chronic heart failure in CIBIS II trial. Circulation 2001; 103:1428-1433.
19. Salpeter SR, Ormiston TM, Salpeter EE, Poole PJ, Cates CJ. Cardioselective beta- blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 2003; 97:1094-1101.
20. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 4:CD003566.
21. DorowP, Clauzel AM, Capone P, Mayol R, Mathieu M. A comparison ofceliprolol and chlorthalidone in hypertensive patients with reversible bronchial obstruction.JCardiovasc Pharmacol 1986; 8 (Suppl.4):S102-S104.
22. Fenster PE, Hasan FM, Abraham T, Woolfenden J. Effect of metoprolol on cardiac and pulmonary function in chronic obstructive pulmonary disease. Clin Cardiol 1983; 6:125-129.
23. Sorbini CA, Grassi V, Tantucci C, Todisco T, Motolese M. Acute effects of oral metoprolol on ventilatory function in patients with chronic obstructive lung disease. Acta Ther 1982; 8:5-16.
24. McGavin CR, Williams IP. The effects of oral propranolol and metoprolol on lung function and exercise performance in chronic airways obstruction. Br J Dis Chest 1978; 72:327-332.
25. Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31:143-147.
26. Macquin-Mavier I, Roudot-Thoraval F, Clerici C, George C, Harf A. Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction. Br J Clin Pharmacol 1988; 26:279-284.
27. Butland RJ, Pang JA, Geddes DM. Effect ofbeta-adrenergic blockade on hyperven- tilation and exercise tolerance in emphysema. J Appl Physiol 1983; 54:1368-1373.
28. Barnes PJ. Distribution of receptor targets in the lung. Proc Am Thorac Soc 2004; 1:345-351.
29. Ellis ME, SahayJN, Chatterjee SS, Cruickshank JM, Ellis SH. Cardioselectivity of atenolol in asthmatic patients. Eur JClin Pharmacol 1981; 21:173-176.
30. Dorow P, Tonnesmann U. Dose-response relationship ofthe beta-adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis. Eur JClin Pharmacol 1984; 27:135-139.
31. Tattersfield AE, Cragg DJ, Bacon RJ. Assessment of beta-adrenoceptor selectivity of a new beta-adrenoceptor antagonist, bisoprolol, in man. Br J Clin Pharmacol 1984; 18:343-347.
32. Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity of three beta1-selective beta-blockers. JClin Pharm Ther 2003; 28:179-186.
33. Dorow P, Thalhofer S, Bethge H, DisselhoffG, Wagner G. Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study. J Cardiovasc Pharmacol 1990; 16(Suppl. 5):S36-S44.
34. On LS, Boonyongsunchai P, Webb S, Davies L, Calverley PM, Costello RW. Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:1320-1325.
35. Wellstein A, Palm D, Belz GG, Butzer R, Polsak R, Pett B. Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy. Eur Heart J1987; 8(Suppl. M):3-8.
36. Agostoni P, Contini M, Cattadori G, Apostolo A, Sciomer S, Bussotti M,Palermo P, Fiorentini C. Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? Eur J Heart Fail 2007; 9:827-833.
37. Walke LM, Byers AL, Tinetti ME, Dubin JA, McCorkle R, Fried TR. Range and severity of symptoms over time among older adults with chronic obstructive pulmonary disease and heart failure. Arch Intern Med 2007; 167:2503 -2508.
38. Sneed NV, Paul S, Michel Y, Vanbakel A, Hendrix G. Evaluation of 3 quality of life measurement tools in patients with chronic heart failure. Heart Lung 2001; 30:332-340.
39. Havranek EP, McGovern KM, Weinberger J, Brocato A, Lowes BD, Abraham WT. Patient preferences for heart failure treatment: utilities are valid measures of health-related quality of life in heart failure. JCard Fail 1999; 5:85-91.
40. Guell R, Casan P, Belda J, Sangenis M, Morante F, Guyatt GH, Sanchis J. Long-term effects ofoutpatient rehabilitation ofCOPD: a randomized trial. Chest 2000; 117:976-983.
41. Jones P, Lareau S, Mahler DA. Measuring the effects of COPD on the patient.Respir Med 2005; 99(Suppl. B):S11 -S18.
42. Jones PW. Health status measurement in chronic obstructive pulmonary disease.Thorax 2001; 56:880-887.
43. O'Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, Knobil K Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006; 130:647-656.
44. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1:681 -686.
45. Delclaux B, Orcel B, Housset B, Whitelaw WA, Derenne JP. Arterial blood gases in elderly persons with chronic obstructive pulmonary disease (COPD). Eur Respir J1994; 7:856-861.
46. Agostoni P, Contini M, Magini A, Apostolo A, Cattadori G, Bussotti M, Veglia F,Andreini D, Palermo P. Carvedilol reduces exercise-induced hyperventilation: a benefit in normoxia and a problem with hypoxia. Eur J Heart Fail 2006; 8:729-735.
47. Brashear RE, Ross JC. Effect ofdipyridamole and propanolol on pulmonarydiffus- ing capacity during rest and exercise. Am Rev Respir Dis 1968; 98:1048-1051.